

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ZHENG *et al.*

Appl. No.: 10/560,075

§ 371 Filing Date: December 9, 2005

For: **Antineoplastic Agents Targeted Via
GLUT Transporters**

Confirmation No.: 9659

Art Unit: 1623

Office: BLAND, Layla D.

Atty. Docket: 1694.0580004/JMC/CMB/KHR

Reply Under 37 C.F.R. § 1.114

Mail Stop RCE

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated May 7, 2009, Applicants submit the following Remarks, which begin on page 2 of this paper.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.